Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Novartis Ag (NVSEF) over the last 12 years, with Q4 2025 value amounting to $36.0 million.

  • Novartis Ag's Exchange Rate Effect rose 11146.5% to $36.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $576.0 million, marking a year-over-year increase of 29328.86%. This contributed to the annual value of $576.0 million for FY2025, which is 29328.86% up from last year.
  • According to the latest figures from Q4 2025, Novartis Ag's Exchange Rate Effect is $36.0 million, which was up 11146.5% from -$22.0 million recorded in Q3 2025.
  • Novartis Ag's Exchange Rate Effect's 5-year high stood at $382.0 million during Q2 2025, with a 5-year trough of -$314.0 million in Q4 2024.
  • Its 5-year average for Exchange Rate Effect is $4.2 million, with a median of -$22.0 million in 2025.
  • In the last 5 years, Novartis Ag's Exchange Rate Effect plummeted by 330000.0% in 2024 and then skyrocketed by 122352.94% in 2025.
  • Over the past 5 years, Novartis Ag's Exchange Rate Effect (Quarter) stood at -$65.0 million in 2021, then surged by 316.92% to $141.0 million in 2022, then rose by 13.48% to $160.0 million in 2023, then tumbled by 296.25% to -$314.0 million in 2024, then skyrocketed by 111.46% to $36.0 million in 2025.
  • Its Exchange Rate Effect stands at $36.0 million for Q4 2025, versus -$22.0 million for Q3 2025 and $382.0 million for Q2 2025.